secwatch.observer — SEC 8-K summary
======================================

Issuer:     Vaxcyte, Inc. (PCVX)
CIK:        0001649094
Form:       8-K
Filed at:   2024-02-27T23:59:59+00:00
Accession:  0000950170-24-021081
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Vaxcyte FY23 net loss $402M; VAX-31 adult Phase 1/2 topline data Q3 2024; cash $1.24B
--------------------------------------------------------------------------------

- Net loss of $402.3M for FY2023 (vs $223.5M in FY2022); cash, equivalents & investments $1.24B as of Dec 31, 2023.
- VAX-31 adult Phase 1/2 study enrollment complete; topline safety, tolerability & immunogenicity data expected Q3 2024.
- VAX-24 adult program Phase 3-ready following End-of-Phase 2 FDA meeting; either VAX-24 or VAX-31 to advance after VAX-31 readout.
- VAX-24 infant Phase 2 enrollment nearing completion; topline data from primary series by end Q1 2025, booster by end 2025.
- R&D expenses $332.3M for FY2023, up 96% YoY due to manufacturing scale-up for PCV programs.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1649094/000095017024021081/0000950170-24-021081-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1649094/000095017024021081/pcvx-20240227.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-021081

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer